Ardagh Metal Packaging S.A. Ordinary Shares (AMBP)

New York, NY – October 13, 2025 – Century Aluminum Company (NASDAQ: CENX) has captured significant attention in the financial markets, with its stock recently hitting a formidable 52-week high. This impressive surge reflects a confluence of strong tailwinds in the global aluminum market and strategic, forward-looking initiatives undertaken by the company.

Ardagh Metal Packaging (AMBP) Q2 earnings beat estimates with $1.455B revenue and $0.08 EPS, driving a pre-market stock rise. Dividend declared.

Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, Impinj, Lufax, Tempus AI, Kymera Therapeutics.

The session on Thursday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

AMBP stock results show that Ardagh Metal Packaging beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

On CNBC's "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Amazon, which hit another high, surpassing the $200 level on Friday.

These at-risk dividend stocks could see further price decreases, dividend reductions or both which is why investors should avoid them.

Jim Cramer can't recommend Twilio due to recent stock downgrade. He prefers Vistra Corp. and Constellation Energy Corp. for energy market.

AMBP stock results show that Ardagh Metal Packaging missed on revenue for the first quarter of 2024.

Here are three materials stocks to sell that are at risk for another decline with market risk and unfavorable financial results.

Ardagh is poised to benefit from long-term expected global growth for metal cans.

U.S. stocks traded higher, with the Dow Jones gaining over 200 points on Thursday. Here are some big stocks recording gains in today’s session.

Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its EDP1815 Phase 2 trial, in which the primary endpoint was not met.